Please use this identifier to cite or link to this item:
Title: Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders
Authors: Farrah Syazana Khattulanuar
Sekar, Mahendran
Fuloria, Shivkanya
Gan, Siew Hua
Nur Najihah Izzati Mat Rani
Ravi, Subban
Chidambaram, Kumarappan
Begum, Yasmin
Azad, Abul Kalam
Jeyabalan, Srikanth
Dhiravidamani, Arulmozhi
Thangavelu, Lakshmi
Lum, Pei Teng
Subramaniyan, Vetriselvan
Wu, Yuan Seng
V. Sathasivam, Kathiresan
Fuloria, Neeraj Kumar
Keywords: Cardioprotection
Cardiovascular disorders
Drug development
Molecular mechanism
Issue Date: Feb-2022
Publisher: MDPI
Citation: Farah Syazana Khattulanuar, F. S., Sekar, M., Fuloria, S., Gan, S. H., Nur Najihah Izzati Mat Rani, Ravi, S., Chidambaram, K., Begum, Y., Ferdosh, S., Jeyabalan, S., Dhiravidamani, A., Thangavelu, L., Lum, P. T., Subramaniyan, V., Wu, Y. S., Sathasivam, K. V., & Fuloria, N. K. (2022). Tilianin: a potential natural lead molecule for new drug design and development for the treatment of cardiovascular disorders. Molecules, 27(3), 673.
Abstract: Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.
ISSN: 14203049
Appears in Collections:Journal Articles

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.